| Roche Holding Ltd | 271.2500 / +0.02% |
| Date/Time | 03/19 / 20:58 |
| Chg. / Chg.(%) | 0.0500 / +0.02% |
| Bid | - |
| Ask | - |
| Open | 271.2500 |
| Previous Close | 271.2000 |
| High | 271.2500 |
| Low | 270.7500 |
| Volume [USD] | 235,132.7500 |
| Volume [Units] | 867 |
| Price fixings | 4 |
| ISIN | CH0012032048 |
| Security | RHHVF |
| Exchange | Nasdaq Other OTC |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| SIX Swiss Ex.. | 270.00 |  |
1,290,118 |
| London Inter.. | 271.25 | |
299,380 |
| Cboe Europe .. | 270.55 | |
194,409 |
| Turquoise | 270.55 | |
95,980 |
| Xetra | 241.00 | |
4,267 |
| TradeGate | 237.450 | |
3,252 |
| Stuttgart | 238.100 | |
1,723 |
| Frankfurt | 237.950 | |
956 |
| Nasdaq Other.. | 271.2500 | |
867 |
| Borsa Italia.. | 239.70 | |
150 |
| München | 238.05 | |
25 |
| Berlin | 237.95 | |
22 |
| Düsseldorf | 238.00 | |
0 |
| Hamburg | 239.10 | |
0 |
| Lang & Schwa.. | 237.047 | |
|
| gettex | 238.250 | |
|
| Mexico | 5,220.00 | 256 | |
| Mexico | 4,744.44 | 32 | |
| Borsa Italia.. | 239.70 | ||
| EUREX | Options | ||
News
- FDA approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
03/19/2019 / 07:00 - GlobeNewswire - European Commission approves Roche's MabThera (rituximab) for a rare autoimmune disease
03/15/2019 / 07:00 - GlobeNewswire - European Commission approves Roche's Hemlibra for people with severe haemophilia A without factor VIII inhibitors
03/14/2019 / 07:00 - GlobeNewswire - Roche's VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane
03/11/2019 / 07:03 - GlobeNewswire - FDA grants Roche's Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer
03/11/2019 / 07:00 - GlobeNewswire
Real-time